Tango Therapeutics
TNGX
194 hedge funds and large institutions have $3.77B invested in Tango Therapeutics in 2026 Q1 according to their latest regulatory filings, with 59 funds opening new positions, 64 increasing their positions, 56 reducing their positions, and 32 closing their positions.
147% more capital invested
Capital invested by funds: $1.53B → $3.77B (+$2.24B)
100% more funds holding in top 10
Funds holding in top 10: 7 → 14 (+7)
84% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 32
14% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 56
14% more funds holding
Funds holding: 170 → 194 (+24)
13% more call options, than puts
Call options by funds: $2.12M | Put options by funds: $1.87M
1.68% less ownership
Funds ownership: 128.01% → 126.33% (-1.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$164M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$98M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
+$55.8M |
| 4 |
Holocene Advisors
New York
|
+$54.7M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$30.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$55.2M |
| 2 |
SL
Siren LLC
Greenwich,
Connecticut
|
-$34.9M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$32.3M |
| 4 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$31.1M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$28.8M |
TNGX Hedge Fund Activity: Q1 2026 in Review
194 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Tango Therapeutics (TNGX) for Q1 2026, worth a combined $3.77B — up 147% from $1.53B a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new TNGX positions and 32 closed out — a net gain of 27 holders — while 64 added to existing stakes and 56 trimmed.
The largest buyer was RTW Investments, adding an estimated $164M. The largest seller was Farallon Capital Management, cutting an estimated $55.2M.
- 194 institutional investors held Tango Therapeutics (TNGX) as of Q1 2026, up from 170 in Q4 2025.
- Funds reported $3.77B of Tango Therapeutics stock for Q1 2026, up 147% quarter-over-quarter.
- 59 funds opened new Tango Therapeutics positions in Q1 2026 and 32 closed out, a net change of +27 holders.
- The largest Tango Therapeutics buyer in Q1 2026 was RTW Investments, an estimated $164M added.
- The largest Tango Therapeutics seller in Q1 2026 was Farallon Capital Management, an estimated $55.2M sold.
Based on aggregated 13F filings for Q1 2026.